# Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

> **NCT03964012** · PHASE3 · COMPLETED · sponsor: **Serum Institute of India Pvt. Ltd.** · enrollment: 1800 (actual)

## Conditions studied

- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** NmCV-5
- **BIOLOGICAL:** Menactra

## Key facts

- **NCT ID:** NCT03964012
- **Lead sponsor:** Serum Institute of India Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-20
- **Primary completion:** 2020-02-23
- **Final completion:** 2021-03-04
- **Target enrollment:** 1800 (ACTUAL)
- **Last updated:** 2021-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03964012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03964012, "Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03964012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*